surgicalscience

Presentation of Year-end Report 2025

CEO comments – Q4 2025

- **In Q4, Surgical Science continued to take steps in the right direction**
  - Net sales of SEKm 269, 7% growth. 15% growth adjusted for FX
  - Adjusted EBIT at 17%, in line with financial targets

- **Mixed performance in Educational products with 4% growth**
  - Continued high activity in ultrasound and strong demand globally, with sales up 48%
  - Profitability improvement efforts are starting to have a positive impact, but were offset by adverse currency effects
  - New distributor program launched. Impact expected in Q1 2026

- **Industry/OEM performed well with sales increasing by 10%**
  - All time high license sales of SEKm 92, from Intuitive and several other customers
  - Continued strong development of the robotic surgery market, with more players and bigger pipeline of robotics projects
  - Continued strong interest for the newly launched RobotiX Express platform
  - Pipeline of ongoing medical device development projects up 15%, repeat customers exceeding 70%

- **New strategy presented at Capital Markets Day in December.** Focus on increased market penetration and profitable growth across the five defined market segments

Q4: Profitability in line with financial targets



	Q4	Q1 2024	Q2	Q3	Q4	Q1 2025	Q2	Q3	Q4
Industry/OEM	104,6	109,1	102,4	103,6	126,5	127,7	99,1	124,7	139,3
Educational Products	122,7	79,1	110,1	128,3	125,0	122,9	110,1	139,0	129,5

Q4:

- Net sales up 7% to SEKm 268.9 (251.5). In local currencies up 15%. SEKm 14.2 from IU.
- Educational Products up 4% (-8% excl IU). Regions: Europe +4%, Asia -21%, Americas +43%.
- Industry/OEM up 10%. License revenues up 21%, SEKm 92.3 (76.4). Sim sales SEKm 21.4 (42.5). Dev rev's SEKm 21.5 (4.7).

FY2025:

- Net sales up 12% to SEKm 992.3 (884.1). In local currencies up 19%. SEKm 75.3 from IU.
- Educational Products sales up 13% to SEKm 501.5 (442.5).
- Industry/OEM sales up 11% to SEKm 490.8 (441.6).

surgicalscience

Revenue streams



Development revenue	6,2	8,8	8,2	9,5	4,7	10,5	22,3	21,9	21,5
License revenue	75,9	63,2	67,1	65,0	76,4	83,8	58,9	65,5	92,3
Service revenue	20,2	24,9	22,2	22,2	20,9	21,9	22,8	22,6	23,8
Simulators	125,0	91,3	114,9	135,2	149,6	134,4	105,2	153,6	131,2

- License rev's: 34% (30) of total revenues. Intuitive sales strong both in terms of dV5 and older generations. Larger batch order from another robotic customer.
- Simulator sales down 12%.
- Continued strong development rev's. Consists of both robotics' projects and sales of simulators w/in Indu. For the Q revenues from project in Southeast Asia.
- Stable service revenues.

surgicalscience

Costs and EBIT margin Q4 2025

Costs/margin as a percentage of sales



- Gross margin 66% (68). Higher license revenues positive, but currency and inclusion of IU negative effect.
- Sales: 17% (20) of sales. SEKm 3 in tariffs on simulators from non-US production units.
- Admin: 9% (9) of sales. Increased costs related to for example internal dividend and CMD.
- R&D: 22% (21) of sales. Activated costs SEKm 9.5 (10.2). SEKm 3 restructuring in Seattle.
- Other: Option programs, FX-effects.
- EBIT SEKm 40.1 (39.1), 15% (16). EBIT for IU SEKm -4.8.

FY2025:

- EBIT adjusted for acquisition and restructuring costs 10% (16). Adjusted for FX effects 17%.

surgicalscience

Organization

No of employees at end of period: 313 (274)





Offices / Development sites

* Other: Primarily Germany and China.

surgicalscience

Adjusted EBIT*



Q4:

- Adjusted EBIT SEKm 45.7. Adjusted for restructuring costs SEKm 48.4 (45.3), margin 18% (18).

FY2025:

- Adjusted EBIT SEKm 91.8. Adjusted for acquisition and restructuring costs SEKm 122.4 (168.7), margin 12% (19).

*Excluding acquisition and restructuring costs related to IU in Q1 and Q3 2025 and Seattle in Q4 2025.

surgicalscience

Finance net and taxes

Q4:

- Finance net for the quarter SEKm 2.4 (0.3). Interest on bank balances, revaluation of internal loans and IFRS 16 effect.
- Tax expense for the quarter SEKm -9.2 (-3.2).
- Net result for the quarter SEKm 33.3 (36.3).

FY 2025:

- Finance net for the year SEKm 31.3 (13.8). Interest on bank balances, revaluation of internal loans and IFRS 16 effect.
- Tax expense for the year SEKm -33.3 (-26.4).
- Net result for the year SEKm 66.8 (131.6).

surgicalscience

Cash flow



- Cash flow from operating activities SEKm 72.9 (56.7). Change in working capital SEKm -3.0 (-2.2). Inventory unchanged, A/R decreased.
- Cash flow from investing activities SEKm -15.1 (-12.1) mainly investments in development costs. SEKm 3.2 invested in production facility in Tel Aviv.
- Cash flow from financing activities SEKm -25.7 (240.0).
- Cash at end of period SEKm 616.4 (968.2).
- A/R as % of sales LTM at good level.

surgicalscience

surgicalscience

Thank you

Find out more at:
www.surgicalscience.com